Summary We have examined the role of the aromatase inhibitor 4-hydroxyandrostenedione (4-OHA) in the prevention of mammary tumourigenesis in experiments involving 170 rats. We first demonstrated a prophylactic effect of 4-OHA (50 mg/week) in reducing tumour incidence over a 30 week period compared to controls (P = 0.04). We repeated the experiment to determine optimum dose and duration of therapy. Although 4-OHA again prevented tumour development (P<0.0005), there was no difference between the standard (50 mg/week) dose and the higher dose (100 mg/week). Rats were randomised at 30 weeks to either stop or to continue prophylactic therapy; marginal benefit in tumour free survival in continuing therapy was observed (P = 0.03). We conclude that 4-OHA is an effective agent in preventing carcinogen-induced mammary tumours in rats and further studies of the role of oestrogen synthesis inhibitors in the prevention of human mammary tumours may be indicated.
There is now substantial evidence that oestrogens have a major role in the etiology of breast cancer and that antiendocrine agents used prophylactically may diminish the incidence of the disease (Jordan et al., 1980) .
In premenopausal women, ovariectomy reduces breast cancer incidence (Trichopoulos et al., 1972) , whilst in postmenopausal women an analogous reduction of serum oestradiol is best achieved by aromatase inhibition (Coombes et al., 1984 ). An alternative strategy would be to use an antioestrogen but the anti-oestrogens in current use notably tamoxifen, are all weak agonists as well as being potent antagonists. Despite these disadvantages, tamoxifen has become the most widely used agent in postmenopausal patients as a means of preventing distant recurrence after primary tumour excision (Early Breast Cancer Trialists' Collaborative Group, 1989 ) and has been suggested as a candidate for preventing mammary tumourigenesis (Gazet, 1986) .
It has already been shown that tamoxifen and 4-hydroxyandrostenedione (4-OHA) cause significant tumour regression of nitrosomethylurea (NMU) induced rat mammary tumours (Wilkinson et al., 1986) . NMU-induced tumours are biologically similar to hormone responsive human breast carcinomas in that they contain significant amounts of oestrogen receptor (ER), (Williams et al., 1981) . It is likely that most early human breast carcinomas are ER positive, but as they become more undifferentiated they lose their ability to synthesise ER and growth becomes independent of oestrogen stimulation (Taylor et al., 1982) . As such the prophylaxis of human breast tumourigenesis by early endocrine intervention is receiving increased attention (Gazet, 1986; Fentiman, 1989; Powles et al., 1989) .
Our paper reports on the effects of 4-OHA on the development of NMU-induced rat mammary carcinomas, and examines the effect of drug dosage and duration of preventive therapy.
Methods
Carcinogen exposure Three batches, 40 animals in the first two batches and 90 in the third, of female Ludwig/Wistar/Olac rats (OLAC 1976 Ltd, Oxon, England) , were kept at 19°C in isolators with a regimen of 12 h light/day. They were fed C.R.M. diet (Labsure, Croydon, England) and received water ad libitum. Nitrosomethylurea (NMU) was dissolved in distilled water at 12.5 mg ml-' and adjsuted to pH 5.4 with acetic acid. At 45-50 days of age, the rats received 0.5 ml NMU/rat (5 mg 100 g-' body weight) subcutaneously in both flanks on days 0, 14 and 28. When transferred to the institute, the animals were kept at 22-23°C with 12 h light/12 h dark (7 am-7 pm-light cycle) and fed a diet rich in polyunsaturated fats (14% fat diet obtained from Labsure, Croydon, England).
Anti-endocrine injection schedule Study I (batch I and batch 2) Batch 1 started the study 3 months before batch 2. Within 1 week after the final carcinogen injection, all animals were divided randomly into two groups. The control group received intramuscularly, 0.2 ml, 0.9% NaCl solution per rat per week. The treatment group received 50 mg 4-hydroxyandrostenedione (4-OHA) (CibaGeigy, Basel, Switzerland) subcutaneously per rat per week. This was supplied as a sterile microcrystalline powder suspended in physiological saline immediately before administration. All animals were injected once a week for 30 weeks.
Study 2, batch 3 In batch 3, each animal was randomised to receive either 0.2 ml, 0.9% NaCI solution, 4-OHA 50 mg 5-6 weekly or 100 mg week for 30 weeks. Each group therefore contained 30 animals. At 30 weeks, those rats remaining in the trial were randomised a second time (within their respective treatment group) either to continue treatment until 60 weeks or to stop therapy.
At the start of the anti-endocrine injection schedule all rats were approximately the same age and weight and free of tumours.
Assessment of mammary tumour incidence Animals were examined weekly for palpable tumours, with date of tumour appearance and a map of tumour location recorded for each rat. Tumour size was measured weekly using Vernier calipers. If a tumour attained a size of 15 mm in diameter, the rat was sacrificed by cardiac puncture and tumours excised. Rats which did not develop a tumour by the end of the study period (study 1 = 30 weeks, study 2 = 60 weeks) were sacrificed by cardiac puncture. The incidence of tumours in the control group is similar to our previous studies (Wilkinson et al., 1986 ).
Statistical methods Standard survival analysis methods, namely Kaplan-Meier survival curves and the Logrank test, were used to compare tumour occurrence and survival between groups. Since small tumours often regress spontaneously, only those tumours 10 mm in diameter or greater were considered in the analysis of tumour incidence. Sacrifice of an animal due to the occurrence of a 15 mm tumour was considered as a death.
The relative risk of tumour occurrence and death in treated rats compared with controls and the possibility of a treatment interaction, were estimated using Cox regression (Cox & Oakes, 1984) . Table I There is also some suggestion that benefit of continuing therapy is largely confined to the 50 mg group; we observe a significant benefit in terms of tumour free survival of continuing treatment for the 50 mg group (Logrank test = 7.16 d.f. 1 P = 0.007), but not for the 100 mg group (Logrank test = 0.33 d.f. = 1 P = 0.54). We observe, however, no evidence of an interaction between duration of treatment and dose of 4-OHA given (test for interaction P = 0.16).
Similar results are obtained when considering overall survival (Logrank test = 5.11 d.f. = 1 P = 0.Q24 and Logrank test =0.38d.f.= 1P =0.54 for the 50mg and 100mg groups respectively). Again no evidence of an interaction with dose of 4-OHA (test for interactiQn P = 0.25) is observed.
Survival estimates at 60 weeks in each of these groups are shown in Table III Combining data from both studies, the estimated relative risk of death during the first 30 weeks in the control group compared with the 4-OHA treated groups is 5.8 (95% CI 2.7, 12.3). The corresponding relative risk for tumour incidence is 4.5 (95% CI, 2.4, 8.1).
Discussion
Our results show that 4-OHA can prevent mammary tumour development and improve survival in rats bearing mammary tumours. During the first 30 weeks 4-OHA prevented development of an estimated 78% of tumours and 83% of deaths.
4-OHA is an important new agent in the treatment of human breast cancer (Coombes et al., 1984; Goss et al., 1986) , and is effective in lowering serum oestradiol in postmenopausal women. There are no other endocrine effects known except that, at high oral dosing, its low androgenicity (1%) is seen, reflected by a reduction in sex hormone binding globulin. 4-OHA is not effective in premenopausal women when administered as a single agent. We do however, see a further reduction in serum oestradiol when 4-OHA is given in conjunction with an LHRH analogue (Stein et al., 1989) . Our results suggest that low dose, longer duration therapy may be the more effective treatment. The reason for this is not clear. It is possible that at higher doses the androgenic effect of 4-OHA impedes its activity. Alternatively, a hitherto unknown metabolite may have oestrogenic activity at higher dose. In any event, our results suggest that high dose aromatase inhibition is not needed to prevent mammary carcinogenesis.
Several further questions remain before this therapy can be advocated for women at high risk of developing breast cancer. Firstly, there may be more powerful aromatase inhibitors in development. We have already shown that CGS16949A, an imidazole derivative, is effective in patients with breast cancer (Stein et al., in press) and this is also effective in rats bearing mammary tumours (Schieweck et al., 1988) . Secondly, longer term toxicity testing is needed in both animals and humans, and thirdly it is important to determine that 4-OHA is as effective as tamoxifen as an adjuvant treatment in patients.
